文献速递前列腺增生与排尿功能障碍男科与性医学

钛涂层经闭孔吊带治疗男性压力性尿失禁:内向外单切口技术至少12个月随访研究

Titanized Transobturator Sling Placement for Male Stress Urinary Incontinence Using an Inside-out Single-incision Technique: Minimum 12-Months Follow-up Study.
PubMed 文献 · Urology · 2018-03-01

该前瞻性研究纳入44例根治性前列腺切除或经尿道前列腺切除术后尿失禁男性,行钛涂层两臂吊带(TiLOOP Male)内向外单切口植入,保留球海绵体肌。中位随访25个月,治愈率54.6%,改善率22.7%,总成功率77.3%,主观成功率75%,满意度75%;BMI≥30及既往放疗或HIFU为失败独立预测因素。

要点

  • TiLOOP Male吊带治疗男性轻中度尿失禁中期成功率77.3%、满意度75%
  • 肥胖及既往放疗或HIFU患者失败风险更高,术前应告知
  • 内向外单切口技术安全,多数并发症为Clavien-Dindo I级

核心结论

  • TiLOOP Male吊带提供良好且稳定的中期控尿结果,内向外入路安全,吊带及单切口技术耐受性满意。
  • 肥胖及既往放疗或高强度聚焦超声患者应知晓其失败风险较高。

研究设计与样本

  • 前瞻性研究,2013年1月至2016年6月连续纳入44例因根治性前列腺切除(39例)或经尿道前列腺切除(5例)所致尿失禁患者。
  • 所有患者接受经闭孔两臂钛涂层吊带(TiLOOP Male)植入,采用内向外单切口技术,保留球海绵体肌。
  • 术后评估包括尿流率、尿垫计数、IPSS-Short Form、IIQ-7、PGI-I、OAB问卷、IPSS及满意度(是/否)。

主要发现

  • 轻度尿失禁11/44(25%)、中度26/44(59%)、重度7/44(16%)。
  • 中位随访25个月(范围12-55,至少12个月),治愈24例(54.6%),改善10例(22.7%),总成功率77.3%。
  • 前6个月内失败10例(22.7%);零尿垫率50%。
  • 主观成功(PGI-I非常或很大改善)33例(75%);满意度33例(75%)。
  • ICIQ-SF、ICIQ-QoL及IIQ-7平均评分改善有统计学意义;尿流率参数术后无变化,多数并发症为Clavien-Dindo I级。

关键数值与推荐

  • 成功结局定义为治愈(不使用尿垫或仅使用1块干燥「安全」尿垫)或改善(尿垫计数减少至少50%)。

临床怎么用

  • 对于根治性前列腺切除或经尿道前列腺切除术后男性轻中度压力性尿失禁,可考虑TiLOOP Male吊带内向外单切口植入。
  • 术前应评估BMI及既往放疗或HIFU史,对高风险患者充分告知失败可能性。

局限性

  • 样本量较小(44例),随访时间有限(中位25个月,范围12-55个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate prospectively midterm outcomes of a new titanium-coated fixed polypropylene sling for male stress urinary incontinence. MATERIALS AND METHODS: From January 2013 to June 2016, 44 consecutive patients with incontinence caused by radical prostatectomy (39) or transurethral resection of prostate (5) underwent transobturator 2-arm titanium-coated sling (TiLOOP Male) implantation with an inside-out, single-incision technique, leaving the bulbourethral muscle in place. Patients have been assessed postoperatively with uroflowmetry, pad count, International Prostate Symptom Score-Short Form, Incontinence Impact Quetionnaire-7, Patient's Global Impression of Improvement, Overactive Bladder questionnaire, International Prostate Symptom Score, and satisfaction (yes or no). Successful outcome included cure (no pad use or 1 dry "security" pad) or improvement (reduction of at least 50% of the pad count). RESULTS: Evaluated patients had mild (11 of 44, 25%), moderate (26 of 44, 59%), or severe (7 of 44, 16%) incontinence. After a median follow-up of 25 months (range 12-55, minimum 12 months), 24 (54.6%) patients were cured and 10 (22.7%) were improved, which was a global success rate of 77.3%. There were 10 (22.7%) failures in the first 6 months. Zero pad rate was 50%. Subjective success (Patient's Global Impression of Improvement very much or much improved) was achieved in 33 (75%) patients. Mean scores of ICIQ-SF, ICIQ-QoL, and IIQ-7 improved to a statistically significant extent. Satisfaction was reported by 33 (75%) patients. Uroflowmetry parameters were unchanged postoperatively, and most of the complications were Clavien-Dindo grade I. Body mass index ≥30 and previous irradiation or high-intensity focused ultrasound were independent predictors of failure. CONCLUSION: TiLOOP Male provided favorable and stable midterm continence outcomes. The inside-out approach was safe, and the tolerability of the sling and the single-incision technique was satisfactory. Patients with obesity and previous irradiation or high-intensity focused ultrasound should be aware of their higher risk of failure.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sacco E, Gandi C, Vaccarella L, et al. Titanized Transobturator Sling Placement for Male Stress Urinary Incontinence Using an Inside-out Single-incision Technique: Minimum 12-Months Follow-up Study. Urology. 2018. PMID: 29501713. doi:10.1016/j.urology.2018.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。